Stockscreener 앱 받기
31.66
0.88%
-0.292
전일 마감가:
$31.95
열려 있는:
$31.93
하루 거래량:
2.14M
Relative Volume:
0.65
시가총액:
$14.20B
수익:
$2.27B
순이익/손실:
$1.15B
주가수익비율:
12.41
EPS:
2.55
순현금흐름:
$2.80B
1주 성능:
+3.43%
1개월 성능:
+25.08%
6개월 성능:
+10.97%
1년 성능:
+10.43%
1일 변동 폭
$31.49
$32.06
1주일 범위
$30.61
$32.21
52주 변동 폭
$24.05
$32.21
로열티 파마 Stock (RPRX) Company Profile
명칭
Royalty Pharma Plc
전화
(212) 883-0200
주소
110 EAST 59TH STREET, NEW YORK, NY
RPRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
31.66 | 14.20B | 2.27B | 1.15B | 2.80B | 2.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.34 | 113.70B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
685.57 | 75.52B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
666.48 | 39.78B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.61 | 35.34B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
123.30 | 29.05B | 3.30B | -501.07M | 1.03B | -2.1146 |
로열티 파마 Stock (RPRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-06-03 | 다운그레이드 | UBS | Buy → Neutral |
| 2022-06-14 | 재개 | UBS | Buy |
| 2022-05-13 | 개시 | Scotiabank | Sector Outperform |
| 2022-04-27 | 개시 | Goldman | Buy |
| 2022-04-14 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-04-06 | 재개 | Morgan Stanley | Overweight |
| 2021-10-29 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-07-30 | 개시 | Tigress Financial | Buy |
| 2020-11-09 | 업그레이드 | UBS | Neutral → Buy |
| 2020-07-14 | 개시 | Evercore ISI | In-line |
| 2020-07-13 | 개시 | BofA Securities | Buy |
| 2020-07-13 | 개시 | Citigroup | Neutral |
| 2020-07-13 | 개시 | Cowen | Outperform |
| 2020-07-13 | 개시 | Goldman | Neutral |
| 2020-07-13 | 개시 | JP Morgan | Neutral |
| 2020-07-13 | 개시 | Morgan Stanley | Equal-Weight |
| 2020-07-13 | 개시 | SunTrust | Buy |
| 2020-07-13 | 개시 | UBS | Neutral |
모두보기
로열티 파마 주식(RPRX)의 최신 뉴스
Kearns & Associates LLC Buys New Shares in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Swedbank AB Raises Stake in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma stock gains on MorphoSys bonds sale (RPRX) - Seeking Alpha
Royalty Pharma (RPRX) Announces Sale of MorphoSys Development Funding Bonds - StreetInsider.com
Royalty Pharma Closes Sale of MorphoSys Development Funding Bonds -January 29, 2025 at 09:40 am EST - Marketscreener.com
Royalty Pharma Announces Sale of MorphoSys Development Funding Bonds - EIN News
Subdued Growth No Barrier To Royalty Pharma plc (NASDAQ:RPRX) With Shares Advancing 25% - Simply Wall St
Royalty Pharma (NASDAQ:RPRX) Sees Large Volume IncreaseHere's Why - MarketBeat
Royalty Pharma to Announce Fourth Quarter and Full Year 2024 Financial Results on February 11, 2025 - The Manila Times
Trend Tracker for (RPRX) - Stock Traders Daily
Royalty Pharma (NASDAQ:RPRX) Reaches New 52-Week HighWhat's Next? - MarketBeat
1834 Investment Advisors Co. Buys Shares of 9,500 Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Assenagon Asset Management S.A. Makes New Investment in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Impact Partnership Wealth LLC Purchases Shares of 18,323 Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Why Is Andreas Halvorsen Bullish On Royalty Pharma plc (RPRX) Now? - Insider Monkey
Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst - Benzinga
Wall Street Analysts Predict a 31.15% Upside in Royalty Pharma (RPRX): Here's What You Should Know - Yahoo Finance
Overbrook Management Corp Has $3.02 Million Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Ascendis and Royalty Pharma enter into $150M royalty funding agreement - MSN
Where are the Opportunities in (RPRX) - Stock Traders Daily
14 Best 52-Week High Stocks To Buy According to Analysts - Insider Monkey
Royalty Pharma plc (RPRX): Analysts Recommend This 52-Week High Stocks Now - Insider Monkey
Royalty Pharma: Key Strategic Updates To Be Priced In - Seeking Alpha
Investors Purchase High Volume of Royalty Pharma Call Options (NASDAQ:RPRX) - MarketBeat
Royalty Pharma plc (RPRX) 2900 contracts of July 32.50 calls trade - StreetInsider.com
Pallas Capital Advisors LLC Invests $2.36 Million in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma (RPRX) Crossed Above the 200-Day Moving Average: What That Means for Investors - Yahoo Finance
Royalty Pharma (NASDAQ:RPRX) Is Increasing Its Dividend To $0.22 - Simply Wall St
Royalty Pharma (NASDAQ:RPRX) Has Announced That It Will Be Increasing Its Dividend To $0.22 - Yahoo Finance
Nordea Investment Management AB Decreases Stock Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma plc authorizes a Buyback Plan. - Marketscreener.com
Did Royalty Pharma (RPRX) Close Shortened Trading Week Higher? - MSN
Here’s Why Royalty Pharma plc (RPRX) Led This Week’s Rally - Insider Monkey
These 10 Firms Led This Week’s Rally - Insider Monkey
Royalty Pharma plc (NASDAQ:RPRX) Receives $41.67 Consensus PT from Analysts - MarketBeat
Royalty Pharma’s Strategic Moves and Share Buyback Plan - MSN
10 Firms Close Shortened Trading Week Higher - Insider Monkey
Royalty Pharma plc (NASDAQ:RPRX) Declares Quarterly Dividend of $0.22 - MarketBeat
Royalty Pharma Breaks Above 200-Day Moving AverageBullish for RPRX - Nasdaq
Big Corporate Moves: Acquisitions And Sales Reshape Industries - Finimize
Royalty Pharma simplifies corporate structure with $1.1 billion deal - Marketscreener.com
Royalty Pharma (NASDAQ:RPRX) Shares Gap UpHere's What Happened - MarketBeat
Royalty Pharma to acquire manager, announce buyback program By Investing.com - Investing.com Australia
Royalty Pharma stock rises following RP Management buyout and $3 billion buyback plan - Investing.com Nigeria
Royalty pharma to buy its external manager, announces $3B share buyback - MSN
Royalty Pharma to acquire manager, announce buyback program - Investing.com India
Royalty Pharma to Highlight Accomplishments and Provide Business Update at 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Royalty Pharma Announces Transformative Step in Company's Evolution With Acquisition of its External Manager and $3 Billion Share Repurchase Program - The Manila Times
Royalty Pharma Hits Record $2.8B in Deals, Projects $1.2B Peak Pipeline Royalties - StockTitan
Royalty Pharma (RPRX) Announces Acquisition of its External Manager and $3 Billion Share Repurchase Program - StreetInsider.com
Royalty Pharma Unveils $3B Buyback Plan, Projects $1.6B Savings from Manager Acquisition - StockTitan
로열티 파마 (RPRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.05%
4.57%
자본화:
|
볼륨(24시간):